Longevity & AgingResearch PaperPaywall

PD-L1 levels may help predict who responds to immunotherapy in rare histiocytic cancers

In 26 rare aggressive histiocytic cancers, PD-L1 was common and high levels tracked with better survival and a trend toward response to checkpoint inhibitors.

Sunday, November 15, 2026 0 views
Published in Leuk Lymphoma
Microscope view of stained histiocytic tumor cells with brown PD-L1 membrane staining, antibody molecules binding glowing checkpoint proteins

Summary

Malignant histiocytic neoplasms are rare, aggressive blood cancers with no established effective treatment. Researchers at Mayo Clinic and the University of Alabama at Birmingham examined whether PD-L1, a protein that helps tumors evade immune attack, could predict which patients benefit from immune checkpoint inhibitors. In 26 tumors, 73% were PD-L1 positive (≥1% of tumor cells). Patients whose tumors showed PD-L1 in at least 50% of cells had better overall survival than those with lower expression. Among six patients treated with checkpoint inhibitors, half responded; a literature review found a 64% response rate in 14 additional patients. Pooling all 20 treated patients, responders tended to have higher PD-L1 expression (median 88% vs 30%), though this difference did not reach conventional statistical significance. The findings are hypothesis-generating and need larger studies.

Detailed Summary

Malignant histiocytic neoplasms (MHN) are rare, aggressive cancers arising from macrophage- and dendritic-cell-lineage cells. No treatment is firmly established, and outcomes are often poor. Case reports have hinted that immune checkpoint inhibitors (ICI) can work in some patients, but clinicians lack a way to identify who is likely to benefit.

This study asked whether PD-L1, the checkpoint protein targeted by many ICIs, could serve as that marker. The authors analyzed 26 MHN cases, manually scoring PD-L1 on tumor cells as negative or positive (≥1%). They then examined survival, reviewed outcomes in six of their own patients who received ICI, and combined these with 14 patients from a literature review.

Median age at diagnosis was 59 years, and 73% of tumors were PD-L1 positive. Patients with ≥50% PD-L1 expression had better overall survival than those below 50% (100% vs 42%; P = 0.0324). The overall response rate to ICI was 50% in the six institutional patients and 64% in the 14 literature patients. In the combined group of 20, responders had higher median PD-L1 expression than non-responders (88% vs 30%), but the difference was not statistically significant (P = 0.0737).

Taken together, the data suggest PD-L1 is frequently expressed in MHN and that high expression may mark a subset more likely to respond to ICI and to have better outcomes. This could help prioritize patients for checkpoint blockade while the field awaits stronger evidence.

Important caveats apply. The cohort is very small, and the abstract does not report the follow-up period for the survival comparison. The literature-derived patients may be affected by publication bias favoring reported responders. The PD-L1 and response associations are exploratory. The authors call for larger systematic studies, including ICI given with or without chemotherapy or radiation, to assess durability and efficacy.

Key Findings

  • PD-L1 positivity (≥1% of tumor cells) was found in 73% of 26 malignant histiocytic neoplasms.
  • Tumors with ≥50% PD-L1 expression were linked to better overall survival than those below 50% (100% vs 42%; P = 0.0324).
  • Overall response rate to checkpoint inhibitors was 50% in six institutional patients and 64% in 14 patients from the literature.
  • In 20 pooled ICI-treated patients, responders had higher median PD-L1 than non-responders (88% vs 30%), a non-significant trend (P = 0.0737).
  • Authors conclude ICI is promising in a subset of MHN but needs larger studies, including combination approaches.

Methodology

Retrospective analysis of 26 MHN cases with manual PD-L1 scoring on tumor cells (positive ≥1%), correlated with clinicopathologic features and survival. Response to ICI was assessed in six institutional patients and combined with 14 patients identified through a comprehensive literature review.

Study Limitations

The sample is very small and retrospective, and the PD-L1 and response association did not reach statistical significance (P = 0.0737). Pooling literature cases introduces publication bias and heterogeneity in treatment, scoring and response criteria. The analysis is based on the abstract only, so follow-up duration, confounders and treatment details for the survival comparison are not available.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: